* NantHealth Inc NH.OQ NH.O is expected to show a fall
in
quarterly revenue when it reports results on February 24.
* The Culver City California-based company is expected to
report
a 14.1% decrease in revenue to $16.012 million from $18.64
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for NantHealth Inc is
for a
loss of 8 cents per share. For the same quarter last year, the
company reported a loss of 6 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for NantHealth
Inc is
$3.25, about 74.7% above its last closing price of $0.82.
This summary was machine generated February 23 at 03:04 GMT.
All figures in US dollars unless otherwise stated